NUWELLIS NUWE 深 沪
等待开盘 09-03 09:30:00 美东时间
5.05
-0.050
-0.98%
华盛通- 最 高5.1089
- 今 开5.01
- 成交量 2.70万股
- 最 低 4.9001
- 昨 收 5.10
- 总市值 266.19万
- 52周最高 175.98
- 市盈率 静 --
- 换手率 5.12%
- 52周最低 4.82
- 委 比 -84.19%
- 总股本 52.71万
- 历史最高 2012724000.00
- 量 比 1.16
- 振 幅 4.09%
- 历史最低 4.9001
- 每 手 1
- 风险率 21.19%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Nuwellis Gains FDA Clearance for New Catheter
Nuwellis ( ($NUWE) ) has shared an announcement. On August 21, 2025, Nuwellis, ...
08-21 21:17
Nuwellis Receives FDA 510(k) Clearance for New Dual Lumen Extended Length Catheter
Nuwellis, Inc. has received FDA 510(k) clearance for a new size of its Dual Lumen Extended Length Catheter (dELC), expanding its fluid management platform for hospitals and clinics. The dELC, now available in 11 cm and 15 cm lengths, features coil reinforcement and dual-lumen design for consistent blood flow during ultrafiltration therapy. This clearance aligns with Nuwellis' strategy to simplify fluid management across care settings, including c...
08-21 12:15
Nuwellis Announces Acquisition of Rendiatech, Ltd.
Nuwellis ( ($NUWE) ) has provided an update. On August 19, 2025, Nuwellis, Inc....
08-19 21:13
Nuwellis signs letter of intent to acquire Rendiatech
Nuwellis (NASDAQ:NUWE) has signed a non-binding letter of intent to acquire Israeli-based medical device company, Rendiatech. A 45-day due diligence period has commenced. Should both parties agree to ...
08-19 20:30
Nuwellis Signs Letter of Intent to Explore Acquisition of Rendiatech Ltd., A Real-Time Fluid Monitoring Company
Nuwellis, a medical technology company, has signed a non-binding letter of intent to acquire Rendiatech, an Israeli medical device company specializing in real-time urine flow and acute kidney injury monitoring technologies. The proposed acquisition aims to expand Nuwellis' fluid management platform by integrating continuous renal health monitoring technologies, potentially improving patient outcomes through earlier detection of AKI and dehydrati...
08-19 12:15
Nuwellis, Inc. to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
NuWellis Inc. will present at Webull Financial's Biotech/MedTech webinar on August 21, 2025, at 2:40 PM ET. John Erb, CEO, will discuss the company's fluid management solutions for critically ill patients. NuWellis, based in Minneapolis, focuses on commercializing the Aquadex SmartFlow® system for ultrafiltration therapy.
08-15 12:15
Nuwellis outlines Q3 recovery and strategic shift after resolving $400,000 back order
Earnings Call Insights: Nuwellis, Inc. (NUWE) Q2 2025 Management View John L. Erb, CEO, reported that Nuwellis entered the second quarter with an emphasis on strengthening operational discipline, comm...
08-15 02:38
Earnings Scheduled For August 14, 2025
Companies Reporting Before The Bell • Sunlands Technology (NYSE:STG) is likely ...
08-14 16:32
An Overview of Nuwellis's Earnings
Nuwellis (NASDAQ:NUWE) is set to give its latest quarterly earnings report on T...
08-14 00:02
Nuwellis to Exit International Operations to Accelerate U.S. Revenue Growth and Strategic Focus
Nuwellis, Inc. announced its decision to exit international operations and focus exclusively on the U.S. market due to stronger growth and clinical demand there. The company aims to prioritize investment in high-impact areas like U.S. cardiac surgery, pediatrics, and outpatient care. This strategic move aligns operations with market demand and aims to deliver better patient outcomes and shareholder value. Nuwellis will continue supporting interna...
08-07 12:15
